Similar Survival Rates Among HIV-Positive, HIV-Negative Patients Following Liver Transplant
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Similar Survival Rates Among HIV-Positive, HIV-Negative Patients Following Liver Transplant

COPENHAGEN, Denmark -- April 27, 2009 -- HIV-positive and HIV-negative patients have comparable survival rates following liver transplant, according to a study presented on April 24 at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL).

The study results showed no difference in survival rates at 1 and 5 years. At 1 year, the survival rate was 86.5% for HIV-negative patients and 87.1% for HIV-positive patients.

At 5 years, the survival rate was 74% for HIV-negative patients and 78% for HIV-positive patients.

The findings suggest a good prognosis for HIV-positive patients following liver transplant. However, the study confirmed that coinfection with hepatitis C virus (HCV) is a significant predictor of poorer survival rates in patients with HIV. Survival rates at 1 and 5 years were 73% and 53%, respectively, in HIV-positive patients with HCV versus 87% and 69%, respectively, (P = .047) in HIV-negative patients with HCV.

"Data on long-term outcomes from liver transplantation in HIV patients is limited," said lead author Kosh Agarwal, MD, Institute of Liver Studies, Kings College Hospital, London, United Kingdom. "These study results are valuable confirmation that selected HIV-positive patients are as suitable candidates for liver transplant as HIV-negative patients and should have similar access to treatment."

"However, those patients with coinfection with hepatitis C did less well, emphasising the need for appropriate antiviral therapy early in the course of their HCV-related liver disease," continued Dr. Agarwal. "In the context of coinfection, these data emphasise the need to develop newer and more innovative treatment strategies. These should include exposure to new small molecule therapies for HCV that are currently being explored in mono-infection."

The researchers conducted a prospective analysis of the UK Transplant Database to determine the long-term outcomes in patients with HIV undergoing liver transplant in the UK. They examined 6,315 adult patients, (aged >18 years) undergoing their first liver transplant between March 1994 and April 2008. The patient groups compared in this analysis included: (1) HIV-positive patients who tested negative for both HCV and hepatitis B virus (HBV); (2) HIV-negative patients with HCV; (3) HIV-positive patients with HCV.

The 3 patient groups were comparable according to the Model End Stage Liver Disease (MELD) scores. HIV-positive patients were younger compared with HIV-negative patients (mean 42.2 years versus 51.2; P = .001) and HIV-positive patients coinfected with hepatitis C were younger (mean 39.9 years versus 51.8; P = .0001) than HIV-negative patients with HCV.

SOURCE: European Association for the Study of the Liver

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities